Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $189, which is approximately 45.11% above the present share price of $130.25.
Moussatos expects Ascendis Pharma to post earnings per share (EPS) of -$1.17 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Ascendis Pharma, with an average price target of $190.57.
The analysts price targets range from a high of $210 to a low of $173.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $746 thousand and a net profit of -$124.65 million. The company's market cap is $7.01 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.0% and a 44.72% success rate.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.